Dual Pathway Inhibition — RACP Adult Medicine MCQ

Instant feedback + full explanation. One question, done properly.

ModerateCardiologyDual Pathway InhibitionRACP Adult Medicine

A 55-year-old man with stable CAD and new claudication (ABI 0.6). What antithrombotic modification?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Switch to rivaroxaban 2.5 mg BD + aspirin 100 mg (dual pathway inhibition – COMPASS)

COMPASS trial: rivaroxaban 2.5 mg BD + aspirin reduces MACE + limb events in polyvascular disease (CAD + PAD). PBS-listed in Australia.

Reference: NHF/CSANZ – 2025; COMPASS Trial